TPX-0131

N/A

Report date: 2023/05/27 20:00:21
NME

Base Information

Drug NameTPX-0131
Drug Alias NameTPX-0131
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitors
TargetsAnaplastic lymphoma kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTurning Point Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTurning Point Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A